- ISIN
- US36254L2097
- CUSIP
- 36254L209
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 22, 2017
Highlights
- Market Cap
- $14.85M
- Enterprise Value
- $5.93M
- EPS (TTM)
- -$2.91
- EBITDA (TTM)
- -$36.39M
- Year Range
- $0.26 - $3.85
- ROA (TTM)
- -309.59%
- ROE (TTM)
- -408.27%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GTBP Performance Chart
GT Biopharma, Inc. (GTBP) is down 37.5% since the beginning of the year. At $0 per share, GTBP is trading 87.3% below its 52-week high of $4. Investors who bought $1,000 worth of GTBP shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
GT Biopharma, Inc. (GTBP) has returned -37.53% so far this year and -83.92% over the past 12 months.
GT Biopharma, Inc.
- 1D
- -4.57%
- 1M
- 11.48%
- YTD
- -37.53%
- 6M
- -36.62%
- 1Y
- -83.92%
- 3Y*
- -62.29%
- 5Y*
- -74.53%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
GTBP Monthly Returns History
Based on dividend-adjusted daily data since Sep 22, 2017, GTBP's average daily return is -0.11%, while the average monthly return is -4.23%.
Historically, 37% of months were positive and 63% were negative. The best month was Dec 2020 with a return of +149.4%, while the worst month was Aug 2025 at -49.8%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.
On a daily basis, GTBP closed higher 44% of trading days. The best single day was May 20, 2024 with a return of +150.0%, while the worst single day was Apr 25, 2019 at -40.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.93% | -27.59% | -14.62% | -24.48% | 55.16% | 2.57% | -37.53% | ||||||
| 2025 | -26.89% | 6.73% | -9.66% | 12.56% | 6.61% | 38.76% | -48.04% | -49.76% | -37.24% | 6.94% | 25.97% | -0.62% | -74.26% |
| 2024 | -22.35% | -28.96% | 4.98% | -32.28% | 25.00% | -24.53% | -7.77% | -17.62% | 7.40% | 27.33% | -4.76% | 8.93% | -60.13% |
| 2023 | -11.06% | -12.91% | -19.83% | -30.87% | -40.77% | 38.54% | -11.86% | -5.09% | -7.62% | 3.32% | -11.68% | 15.91% | -71.21% |
| 2022 | 2.62% | 1.60% | -9.43% | -26.74% | 30.81% | 8.33% | -2.01% | -11.95% | -31.78% | 5.68% | -11.29% | -46.32% | -70.96% |
| 2021 | 10.85% | -34.79% | 31.29% | 93.71% | 30.11% | -10.09% | -35.81% | -10.65% | -24.18% | -4.15% | -37.00% | -25.06% | -57.69% |
Benchmark Metrics
GT Biopharma, Inc. has an annualized alpha of -29.84%, beta of 0.57, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 22, 2017.
- This stock participated in 177.31% of S&P 500 Index downside but only -105.07% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.57 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -29.84%
- Beta
- 0.57
- R²
- 0.01
- Upside Capture
- -105.07%
- Downside Capture
- 177.31%
Return for Risk
Risk / Return Rank
GTBP ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for GT Biopharma, Inc. (GTBP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GTBP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.69 | ||
| Sortino ratioReturn per unit of downside risk | -3.90 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 1.37 | -0.51 |
| Calmar ratioReturn relative to maximum drawdown | -0.91 | 2.78 | -3.69 |
| Martin ratioReturn relative to average drawdown | -1.06 | 12.44 | -13.50 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the GT Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GT Biopharma, Inc. was 99.99%, occurring on Apr 29, 2026. The portfolio has not yet recovered.
The current GT Biopharma, Inc. drawdown is 99.99%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.99%Apr 2026 | 8y 6mo | — | 8y 8moOct 2017 - now |
2017 bear market2017 | -31.45%Oct 2017 | 16d | 6d | 22dSep 2017 - Oct 2017 |
Drawdown Indicators
| GTBP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -92.84% | -9.10% | -83.74% |
Max Drawdown (3Y)Largest decline over 3 years | -97.39% | -18.90% | -78.49% |
Max Drawdown (5Y)Largest decline over 5 years | -99.94% | -25.43% | -74.51% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.99% | -1.80% | -98.19% |
Average DrawdownAverage peak-to-trough decline | -92.50% | -10.71% | -81.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 79.04% | 2.03% | +77.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of GT Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how GT Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GTBP in comparison with other companies in the Biotechnology industry. Currently, GTBP has a P/B value of 2.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GTBP
Add GT Biopharma, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GTBP